ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

BioMarin Pharmaceutical and Idorsia Pharmaceuticals side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

BioMarin PharmaceuticalIdorsia Pharmaceuticals
studies on the registry172103
open to participants now183
phase 3 studies under way92
reach primary completion within a year52
programswith a study of their own in two years84

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBioMarin PharmaceuticalIdorsia Pharmaceuticals
Phase 1

BioMarin Pharmaceutical: 1 of its 8 programs at phase 1

  1. BMN 349phase 1
13%
00%
Phase 2

BioMarin Pharmaceutical: 1 of its 8 programs at phase 2

  1. BMN 351phase 2
13%

Idorsia Pharmaceuticals: 1 of its 4 programs at phase 2

  1. ACT-777991phase 2
25%
Phase 3

BioMarin Pharmaceutical: 4 of its 8 programs at phase 3

  1. vosoritidephase 3
  2. migalastatphase 3
  3. BMN 333phase 3
  4. efmirenpase alfaphase 3
50%

Idorsia Pharmaceuticals: 2 of its 4 programs at phase 3

  1. migalastatphase 3
  2. aprocitentanphase 3
50%
Approved, new studies

BioMarin Pharmaceutical: 2 of its 8 programs at approved, new studies

  1. pegvaliaseapproved, new study
  2. RDD to Palynziqapproved, new study
25%

Idorsia Pharmaceuticals: 1 of its 4 programs at approved, new studies

  1. daridorexantapproved, new study
25%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
BioMarin Pharmaceutical3 readouts · 2 phase 3·

BioMarin Pharmaceutical, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. migalastatphase 3 · Dec 31 · NCT04020055
···

BioMarin Pharmaceutical, Apr ’27: 1 program whose next study reaches primary completion

  1. BMN 351phase 2 · Apr 14 · NCT06280209
····

BioMarin Pharmaceutical, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. pegvaliaseapproved, new study · Sep 30 · NCT07477691
·
Idorsia Pharmaceuticals1 readouts · 0 phase 3·······

Idorsia Pharmaceuticals, Jun ’27: 1 program whose next study reaches primary completion

  1. ACT-777991phase 2 · Jun 28 · NCT07667569
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

BioMarin Pharmaceutical

New programs 0

None

Reached a new phase 0

None

Study stopped 4

  • vosoritidephase 2 · terminated Nov 13“BioMarin has decided to discontinue the study after assessing a number of factors, including study feasibil…” · NCT06668805
  • efmirenpase alfaphase 2 · terminated Oct 19 · none of its studies left running“The study was terminated by the sponsor prior to planned completion based on a review of the data across in…” · NCT06462547
  • efmirenpase alfaphase 1 · terminated Oct 15 · none of its studies left running“The study was terminated by the sponsor prior to planned completion based on a review of the data across in…” · NCT05734196
  • efmirenpase alfaphase 3 · terminated Oct 1 · none of its studies left running“The study was terminated by the sponsor prior to planned completion based on a review of the data across in…” · NCT06046820

Primary completion later 0

None

Idorsia Pharmaceuticals

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 1 in all. A program counts in each condition its studies name most.

ConditionBioMarin PharmaceuticalIdorsia Pharmaceuticals
Fabry Diseaseboth · compare here

BioMarin Pharmaceutical in Fabry Disease: 1 program

  1. migalastatphase 3

Their studies: BioMarin Pharmaceutical’s studies of Fabry Disease in search

Idorsia Pharmaceuticals in Fabry Disease: 1 program

  1. migalastatphase 3

Their studies: Idorsia Pharmaceuticals’ studies of Fabry Disease in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetBioMarin PharmaceuticalIdorsia Pharmaceuticals
GLAmigalastatrulemigalastatrule
A target, or a pathogen for a vaccine, known for: BioMarin Pharmaceutical 2 of 8 · Idorsia Pharmaceuticals 3 of 4 programs (5 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.